Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05344274 · ClinicalTrials.gov registry record · Phase 4
Retinal Blood Flow and Autoregulation
A Phase 4 study of Glaucoma, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 4
- Study locations
NCT05344274 is a Phase 4 study of Glaucoma that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 90 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05344274, a Phase 4 study of Glaucoma, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Indocyanine Green Angiography
- BIOLOGICAL Isocapnic Oxygen
- DIAGNOSTIC_TEST Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Study Locations (4)
Maryland
- University of Maryland Faculty Physicians, Inc - Baltimore
- University of Maryland Medical Center - Baltimore
- University of Maryland, Baltimore - Baltimore
- Food and Drug Administration (FDA) - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05344274
The ClinicalTrials.gov registry entry for NCT05344274 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Indocyanine Green Angiography is the first listed.
NCT05344274 reports 4 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05344274 about?
NCT05344274 is a clinical study titled "Retinal Blood Flow and Autoregulation". The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
What is the current status of trial NCT05344274?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2022-05-23. Estimated completion is 2027-09.
What conditions does trial NCT05344274 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT05344274?
The interventions under investigation include: Indocyanine Green Angiography (DIAGNOSTIC_TEST), Isocapnic Oxygen (BIOLOGICAL), Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05344274?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05344274 being conducted?
This trial has 4 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.